Prognostic factors in patients with advanced hepatocellular carcinoma treated with sorafenib

Abstract

Sorafenib was associated with improved survival in both CP-A and CP-B patients. In CP-B patients, baseline AST may be helpful in determining which patients are most likely to benefit from sorafenib.